STAT5

[Scientific Reports] Researchers employed a high-dimensional mass cytometry approach to characterize over 250 cell-specific functional responses in 18 innate and adaptive immune cell subsets exposed to 1G or simulated µG using the Rotating Wall Vessel.

[Cell Death & Disease] Oxytocin receptor overexpression led to an activation of prolactin/p-STAT5 pathway and created a microenvironment that promoted mammary-specific tumorigenesis.

[Blood Cancer Journal] Investigators showed that gilteritinib and CUDC-907, a dual inhibitor of PI3K and histone deacetylases, synergistically induced apoptosis in FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) cell lines and primary patient samples and had striking in vivo efficacy.

[Cell Death Discovery] To explore alternative therapeutics to internal tandem duplication (ITD) of FMS-like tyrosine kinase 3 (FLT3), researchers established a cellular model of monoallelic FLT3ITD/WT cells using the CRISPR-Cas9 system in a human myeloid leukemia cell line.

[Experimental & Molecular Medicine] Researchers generated adipocyte-specific Stat5 conditional knockout mice to investigate the role of STAT5 in the adipogenesis of bone marrow mesenchymal stem cells (BMSCs).

[Oncogenesis] Scientists suggested that the dual inhibition of HDAC and HSP90 could suppress the expression of oncogenic pathways in acute leukemia, and MPT0G449 represented a novel therapeutic for anticancer treatment.